FDA Yaz, Yasmin panel members had financial ties to Bayer

Several committee advisors on a panel charged with weighing the risks and benefits of Yaz and Yasmin have come under scrutiny for their ties to the drugs’ manufacturer. At least four of the members on the panel put together by the Food and Drug Administration have worked for or received money from Bayer.

The committee was organized to discuss the potential increased risks of blood clots and other side effects in women using Yaz and Yasmin. The panel voted 15-11 that the drugs should be kept on the market. A government watchdog agency later discovered that four of the votes in favor of the drugs came from members who received research funding from Bayer or were employed by the company.

The panel also voted 21-5 in favor of the FDA updating the warnings on Yaz and Yasmin to include the increased risks of side effects. A study published in the British Medical Journal (BMJ) has found that women using Yaz or Yasmin are twice as likely to suffer from blood clots.

0 Responses to “FDA Yaz, Yasmin panel members had financial ties to Bayer”



  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s




Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 434 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.


%d bloggers like this: